BRPI0409321A - antigen hybrid, competition and method for inducing an immune response to an infectious agent or tumor antigen, method for treating an infectious disease or cancer, and, peptide - Google Patents

antigen hybrid, competition and method for inducing an immune response to an infectious agent or tumor antigen, method for treating an infectious disease or cancer, and, peptide

Info

Publication number
BRPI0409321A
BRPI0409321A BRPI0409321-6A BRPI0409321A BRPI0409321A BR PI0409321 A BRPI0409321 A BR PI0409321A BR PI0409321 A BRPI0409321 A BR PI0409321A BR PI0409321 A BRPI0409321 A BR PI0409321A
Authority
BR
Brazil
Prior art keywords
antigen
hybrid
inducing
immune response
infectious
Prior art date
Application number
BRPI0409321-6A
Other languages
Portuguese (pt)
Inventor
Jessica Baker Flechtner
Kenya Prince-Cohane
Sunil Mehta
Paul Slusareqicz
Sofija Andjelic
Brian H Barber
Original Assignee
Antigenics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/776,521 external-priority patent/US7420037B2/en
Priority claimed from US10/820,067 external-priority patent/US7309491B2/en
Application filed by Antigenics Inc filed Critical Antigenics Inc
Publication of BRPI0409321A publication Critical patent/BRPI0409321A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6043—Heat shock proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/622—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier non-covalent binding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

"ANTìGENO HìBRIDO, COMPOSIçãO E MéTODO PARA INDUZIR UMA RESPOSTA IMUNE PARA UM AGENTE INFECCIOSO OU ANTìGENO DE TUMOR, MéTODO PARA TRATAR UMA DOENçA INFECCIOSA OU CáNCER, E, PEPTìDEO". Antígenos híbridos compreendendo pelo menos um domínio antigênico, pelo menos um domínio de ligação de proteína de choque térmico, e pelo menos um ligador de peptídeo melhorado no meio são descritos que são utilizáveis para a indução de uma resposta imune ao domínio antigênico quando administrados sozinhos ou em um complexo com pelo menos uma proteína de choque térmico. Os antígenos híbridos e complexos podem ser usados para tratar doenças infecciosas e cânceres que expressam um antígeno do domínio antigênico."HYBRID ANTIGEN, COMPOSITION AND METHOD FOR INDUCING AN IMMUNE RESPONSE TO AN INFECTIOUS OR ANTIGEN TUMOR AGENT, A METHOD FOR TREATING AN INFECTIOUS DISEASE OR CANCER". Hybrid antigens comprising at least one antigenic domain, at least one heat shock protein binding domain, and at least one medium-enhanced peptide linker are described that are useful for inducing an immune response to the antigenic domain when administered alone or in a complex with at least one heat shock protein. Hybrid and complex antigens can be used to treat infectious diseases and cancers that express an antigen domain antigen.

BRPI0409321-6A 2003-04-11 2004-04-09 antigen hybrid, competition and method for inducing an immune response to an infectious agent or tumor antigen, method for treating an infectious disease or cancer, and, peptide BRPI0409321A (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US46246903P 2003-04-11 2003-04-11
US46374603P 2003-04-18 2003-04-18
US50341703P 2003-09-16 2003-09-16
US10/776,521 US7420037B2 (en) 2003-02-13 2004-02-12 Heat shock protein-based vaccines and immunotherapies
PCT/US2004/004340 WO2004071457A2 (en) 2003-02-13 2004-02-13 Improved heat shock protein-based vaccines and immunotherapies
US10/820,067 US7309491B2 (en) 2003-04-11 2004-04-08 Heat shock protein-based vaccines and immunotherapies
PCT/US2004/010983 WO2004091493A2 (en) 2003-04-11 2004-04-09 Improved heat shock protein-based vaccines and immunotherapies

Publications (1)

Publication Number Publication Date
BRPI0409321A true BRPI0409321A (en) 2006-05-23

Family

ID=35539709

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0409321-6A BRPI0409321A (en) 2003-04-11 2004-04-09 antigen hybrid, competition and method for inducing an immune response to an infectious agent or tumor antigen, method for treating an infectious disease or cancer, and, peptide

Country Status (8)

Country Link
EP (1) EP1617804A4 (en)
JP (1) JP2007525448A (en)
KR (1) KR20050121721A (en)
AU (1) AU2004229458B2 (en)
BR (1) BRPI0409321A (en)
CA (1) CA2521809A1 (en)
MX (1) MXPA05010881A (en)
WO (1) WO2004091493A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8541002B2 (en) * 2003-09-12 2013-09-24 Agenus Inc. Vaccine for treatment and prevention of herpes simplex virus infection
AU2006236294A1 (en) 2005-04-19 2006-10-26 Eli Lilly And Company Monovalent and polyvalent synthetic polysaccharide antigens for immunological intervention in disease
CY1112212T1 (en) * 2008-04-24 2015-12-09 Immatics Biotechnologies Gmbh NEW VEGETABLE FORMATS OF VOLUME CONNECTED WITH PARTICULARS OF ANTI-HUMAN LEVEL CELLS (HLA) CLASS I OR II
ATE462442T1 (en) * 2008-04-30 2010-04-15 Immatics Biotechnologies Gmbh NOVEL FORMULATIONS OF TUMOR-ASSOCIATED PEPTIDES THAT BIND TO HUMAN LEUKOCYTE ANTIGENS CLASS I OR II FOR VACCINATIONS
US20140255449A1 (en) * 2011-07-21 2014-09-11 Biotech Tools S.A. Dosage of dnak
AU2016260540B2 (en) 2015-05-13 2021-01-07 Agenus Inc. Vaccines for treatment and prevention of cancer
US11065317B2 (en) 2018-04-26 2021-07-20 Agenus Inc. Heat shock protein-binding peptide compositions and methods of use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9202219D0 (en) * 1992-02-03 1992-03-18 Connaught Lab A synthetic heamophilus influenzae conjugate vaccine
HUP9802819A2 (en) * 1995-08-18 1999-03-29 Sloan-Kettering Institute For Cancer Research Heat shock protein-based vaccines and immunotherapies
CA2308299A1 (en) * 1997-10-31 1999-05-14 Sloan-Kettering Institute For Cancer Research Conjugate heat shock protein-binding peptides
WO2001078772A1 (en) * 2000-04-17 2001-10-25 Mojave Therapeutics Inc. Heat shock protein-based antiviral vaccines
US20040071656A1 (en) * 2001-12-26 2004-04-15 Felix Wieland Modulation of heat-shock-protein-based immunotherapies
US7420037B2 (en) * 2003-02-13 2008-09-02 Antigenics Inc. Heat shock protein-based vaccines and immunotherapies

Also Published As

Publication number Publication date
WO2004091493A2 (en) 2004-10-28
MXPA05010881A (en) 2006-05-31
EP1617804A4 (en) 2007-07-25
EP1617804A2 (en) 2006-01-25
WO2004091493A3 (en) 2006-04-20
AU2004229458A1 (en) 2004-10-28
KR20050121721A (en) 2005-12-27
JP2007525448A (en) 2007-09-06
AU2004229458B2 (en) 2009-11-19
CA2521809A1 (en) 2004-10-28

Similar Documents

Publication Publication Date Title
BR0207283A (en) Reduced immunogenicity modified anti-egfr antibodies
IL192679A0 (en) Aglyco products and uses thereof
BR0113491A (en) Isolated polynucleotide and polypeptide, expression vector, host cell, fusion protein, methods for stimulating and / or expanding tumor protein-specific T cells to stimulate an immune response in a patient, to treat cancer in a patient and to inhibit cancer development in a patient, isolated t-cell population, composition, and use of a component.
ATE474048T1 (en) HER2/NEU FUSION PROTEINS
AR031250A1 (en) COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF CANCER DE PULMON
ES2154738T3 (en) COMPOSITION THAT INCLUDES A RECOMBINANT VIRUS EXPRESSING AN ANTIGEN AND A RECOMBINATING VIRUS EXPRESSING AN IMMUNO STIMULATORY MOLECULA.
BR0316758A (en) Yeast-based vaccines as immunotherapy
PT1157041E (en) ANTIBODIES FOR CANCER THERAPY AND DIAGNOSIS
BR0112111A (en) Enhancement of antibody-cytokine fusion protein-mediated immune responses by combined treatment with immunocytocin uptake enhancers
DE69030172D1 (en) Vaccines against cancer and infectious diseases
BR9712971A (en) Method for producing a vaccine to protect a host against disease caused by a chlamydia chain and immunological composition
CY1107628T1 (en) HUMAN CTLA-4 ANTIBODIES AND USES
AR045056A1 (en) ANTI-NGF ANTIBODIES NEUTRALIZING HUMANS AS SELECTIVE INHIBITORS OF THE NGF ROAD
BR0008161A (en) Use of a therapeutic composition for treating a tumor cell, therapeutic composition, and kit for treating a tumor cell
BR0207067A (en) Method for identifying, isolating and producing antigens for a specific pathogen and its use
PL343245A1 (en) Methods for identifying inducers and inhibitors of proteolytic antibodies, compositions and their uses
BR9612619A (en) Method and composition for reconforming multiepitopic antigens to initiate an immune response
PT1572087E (en) Antibodies against cancer antigen tmeff2 and uses thereof
HUP0302681A2 (en) Javelinization of protein antigens to heat shock proteins
WO2000025722A3 (en) ENHANCED VACCINES COMPRISING SELF AND NON-SELF IgE PORTIONS OR DIMERIC ANTIGENS
BRPI0409321A (en) antigen hybrid, competition and method for inducing an immune response to an infectious agent or tumor antigen, method for treating an infectious disease or cancer, and, peptide
BR0009781A (en) Antiidiotypic antibodies against antibodies that inhibit the binding of immunoglobulin and its high affinity receptor
UY26266A1 (en) ANTIGEN ASSOCIATED WITH TUMORS (R11) LAW 17164
BR0015597A (en) Use of antibodies as vaccines
MX2020001287A (en) Braf-specific tcrs and uses thereof.

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUI DADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2129 DE 25/10/2011.